CYCS

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CYCS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CYCS data layer compared with 23 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CYCS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYCS expression acts as an unfavorable survival marker.

CESC and LUSC are the cancer types where CYCS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
CESCDFSMedianAll0.1740.740.0046view →
LUSCDFSMedianII,III,IV0.1990.748.0066view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CYCS–CESC (DFS)

Kaplan–Meier survival curve for CYCS mutant vs wild-type samples in CESC.

Open the CESC breakdown →

Exploration